Early combined immunosuppression in Crohn's disease

The Lancet

Volumn 371, Issue 9629, 2008, Pages 1995-

  Lees, Charlie W ^a   Satsangi, Jack ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYTOKINE RECEPTOR ANTAGONIST; INFLIXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

CROHN DISEASE; DEMYELINATION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LUNG CANCER; PRIORITY JOURNAL; REMISSION; RISK FACTOR; T CELL LYMPHOMA;

EID: 44849135852     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60859-4     Document Type: Letter

References (5)

1. D'Haens G., Baert F., Van Assche G., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371 (2008) 660-667
2. Mackey A., Green L., Liang L., Dinndorf P., and Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44 (2007) 265-267
3. Lees CW, Ironside J, Wallace W, SatsangiJ. Resolution of non-small cell lung cancer following withdrawal of anti-TNF therapy. N Engl J Med (in press).
4. Rennard S., Fogarty C., Kelsen S., et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175 (2007) 926-934
5. Koebel C., Vermi W., Swann J., et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450 (2007) 903-907